Key result
The acarbose test formulation demonstrated bioequivalence to the reference formulation, with geometric mean ratios for CSG,max and AUEC ranging from 94.13% to 99.76% and 90% CIs within 80-125%.
Why the study?
To explore a method for evaluating the bioequivalence of acarbose based on pharmacodynamic parameters.
Does the acarbose test formulation demonstrate bioequivalence to the reference formulation based on pharmacodynamic parameters in human participants?
RCT (n=12)
randomized-sequence
Does the acarbose test formulation demonstrate bioequivalence to the reference formulation based on pharmacodynamic parameters in human participants?
Pre-dose value deduction and direct comparison methods are suitable for assessing acarbose bioequivalence based on pharmacodynamic parameters.
Answers are grounded in this paper and cite their sources.
Demonstrates bioequivalence of acarbose test formulation on pharmacodynamic parameters; confirms direct comparison method suitability for future studies.
Objective To explore a method for evaluating the bioequivalence of acarbose based on pharmacodynamic parameters using a single-dose, randomized-sequence, three-way crossover study of acarbose test (T) and reference (R) formulations. Methods Baseline-adjusted, pre-dose value deduction, and direct comparison methods were used to evaluate the geometric T/R ratios and 90% confidence intervals (CIs) of the ln-transformed pharmacodynamic parameters to identify the most suitable evaluation system. Twelve participants were randomly divided into three groups to receive treatment in the following sequences: TRR, RTR, and RRT, each including a 7-day washout period between treatment periods. The serum glucose concentration (baseline) was determined. Pharmacodynamic parameters, including the maximum reduction in serum glucose concentrations (ΔC SG,max ) and difference of the AUC of glucose between before and after acarbose exposure (ΔAUEC), were tested. Results Using the direct comparison method, the geometric mean ratios of C SG,max , AUEC (0-2h) , and AUEC (0-4h) were 94.13%, 97.82% and 99.76%, respectively. The 90% CIs of the geometric T/R ratios for C SG,max , AUEC (0-2h), and AUEC (0-4h) all fell between 80% and 125%. Conversely, ΔC SG,max and ΔAUEC (0-4h) were less reliable measures of acarbose bioequivalence. Conclusions Pre-dose value deduction and direct comparison methods can be initially considered suitable for assessing acarbose bioequivalence.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2020) reported an RCT. Acarbose test formulation vs. Acarbose reference formulation was evaluated on Geometric T/R ratios of CSG,max, AUEC(0-2h), and AUEC(0-4h) (Geometric mean ratios 94.13%, 97.82%, and 99.76%). The acarbose test formulation demonstrated bioequivalence to the reference formulation, with geometric mean ratios for CSG,max and AUEC ranging from 94.13% to 99.76% and 90% CIs within 80-125%.
Synapse has enriched 10 related papers. Consider them for comparative context: